Does Priority Health Cover Eliquis?

What Is Eliquis and Why Does Coverage Complexity Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that inhibits activated factor Xa, reducing the risk of blood clot formation. The FDA approved apixaban in December 2012 for stroke and systemic embolism prevention in nonvalvular atrial fibrillation, and later for deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and post-surgical DVT prophylaxis following hip or knee replacement. [1]

Coverage complexity matters because anticoagulation is rarely elective. A patient who cannot afford Eliquis may discontinue therapy entirely, a choice that carries serious clinical consequences. The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001) and also reduced major bleeding by 31% (P<0.001). [2] Those outcome differences make formulary barriers a genuine safety concern, not a billing abstraction.

Priority Health is a Michigan-based nonprofit health plan serving over 1 million members across commercial, Medicare Advantage, and Medicaid lines of business. Its formulary decisions follow a pharmacy and therapeutics (P&T) committee review process similar to the one described in AMCP guidelines. [3]

How Priority Health Assigns Eliquis to a Formulary Tier

Priority Health uses a tiered formulary structure. Generic drugs typically sit at Tier 1 or Tier 2, preferred brands at Tier 3, and non-preferred brands at Tier 4 or Tier 5 (specialty). Where Eliquis lands on your specific plan depends on plan year, whether you hold a commercial HMO, PPO, or HSA-compatible plan, and whether your employer negotiated custom formulary terms.

On most Priority Health commercial plans for plan year 2024-2025, branded Eliquis is placed at Tier 3 (preferred brand), meaning a typical 30-day copay of $47 to $100 for members who have met their deductible. Before the deductible is met, members usually pay the full negotiated rate, which sits between $280 and $400 per 30-day supply under commercial contracts. Generic apixaban, which entered the U.S. market in late 2023 after patent litigation settlements with Bristol-Myers Squibb and Pfizer, is generally placed at Tier 2 on updated formularies, with copays closer to $15 to $35. [4]

On Priority Health Medicare Advantage plans, CMS requires that all Part D formularies include at least two drugs in every therapeutic category, and the six protected classes (which do not include anticoagulants specifically) require broader access. Eliquis is typically in a preferred or non-preferred brand tier under Medicare Part D, with a standard initial coverage-phase copay of approximately $47 per fill in 2024. Members who fall into the catastrophic coverage phase pay no more than $0 for most Part D drugs starting in 2025 under the Inflation Reduction Act provisions. [5]

Prior Authorization Requirements for Eliquis Under Priority Health

Prior authorization (PA) is required on the majority of Priority Health commercial plans for Eliquis. The PA criteria generally align with FDA-labeled indications, but plans add administrative hurdles designed to confirm the indication is appropriate and, on some plan designs, to enforce step therapy.

Typical PA criteria that Priority Health P&T reviewers apply include:

• Confirmed diagnosis of nonvalvular atrial fibrillation with a CHA2DS2-VASc score of 2 or higher (or 1 or higher in women), consistent with the 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline recommendation that oral anticoagulation be initiated at those thresholds. [6]
• Confirmed DVT or PE with documented imaging (duplex ultrasound, CT pulmonary angiography, or V/Q scan).
• Post-surgical DVT prophylaxis following total hip or knee arthroplasty, with operative note confirming the procedure.
• Documentation that the prescriber is aware of renal function (serum creatinine, CrCl calculation) and has selected an appropriate dose (5 mg twice daily standard; 2.5 mg twice daily if two of three criteria met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher).

Step therapy is applied on some Priority Health plans, requiring a documented trial of warfarin for at least 90 days OR documentation that warfarin is contraindicated or poorly managed (two or more supratherapeutic or subtherapeutic INR values within a 6-month monitoring period). Michigan law (PA 540 of 2016) provides patients with a right to step-therapy exceptions when the required drug is contraindicated, expected to cause an adverse reaction, or has been tried and failed. Prescribers should invoke this statute explicitly in PA submissions. [7]

A practical framework for prescribers submitting PA requests for Eliquis through Priority Health follows three documentation layers. First, the clinical layer: diagnosis code (ICD-10 I48.11, I48.19, I48.20, I82.401, I26.09, etc.), imaging or EKG documentation, and the specific dosing rationale. Second, the safety layer: renal function labs, hepatic function if relevant, and any bleeding-risk factors that support DOAC preference over warfarin (e.g., labile INR history, frequent falls, drug-drug interaction burden). Third, the formulary exception layer: if generic apixaban is available and tolerated, documenting why branded Eliquis is medically necessary requires a note from the prescriber explaining clinical equivalence concerns or a documented intolerance to a specific excipient in the generic formulation.

Step Therapy and the Generic Apixaban Question

Generic apixaban changed the coverage calculus for Priority Health plans starting in late 2023. Several Priority Health formularies now list generic apixaban at Tier 2 with no prior authorization, while retaining branded Eliquis at Tier 3 with PA. For the majority of patients with atrial fibrillation or VTE, generic apixaban is therapeutically equivalent to branded Eliquis. The FDA's generic drug approval process requires bioequivalence studies demonstrating that the generic product's area under the curve (AUC) and peak concentration (Cmax) fall within 80%-125% of the reference listed drug. [8]

The clinical guidance from the American College of Cardiology's 2023 AF guideline states: "For patients with atrial fibrillation and an indication for anticoagulation, direct oral anticoagulants are recommended over vitamin K antagonists in eligible patients." [6] The guideline does not differentiate between branded and generic formulations of apixaban, meaning a PA denial for branded Eliquis that is paired with automatic approval of generic apixaban generally satisfies the clinical standard of care.

Patients who have legitimate reasons to prefer branded Eliquis over a generic, such as a documented allergy to a tablet excipient present only in the generic formulation, can request a formulary exception. Exception requests require a prescriber-signed letter specifying the medical necessity of the brand.

How to Check Your Specific Priority Health Coverage

Priority Health publishes its formulary on the member portal at priorityhealth.com. The steps are straightforward. Log into your member account, manage to "Benefits and Coverage," then "Drug Coverage," and search by drug name or NDC number. The search returns the current tier, any quantity limits, and whether PA or step therapy applies to your plan.

For Medicare Advantage members, the plan's Annual Notice of Change (ANOC) delivered each September details any formulary changes effective January 1 of the following plan year. If Eliquis moves to a higher tier mid-year, CMS regulations require that Priority Health maintain coverage at the member's current cost-sharing level for the remainder of the plan year. [5]

For employer-sponsored plans, formulary details may differ from the standard Priority Health commercial formulary if the employer self-funds or negotiated a custom drug list. The Summary of Benefits and Coverage (SBC) document, which employers must provide under the ACA, summarizes cost-sharing but may not list every drug tier. The employer's HR department or Priority Health's member services line (1-800-942-0954) can provide the full formulary document.

What Eliquis Costs Out of Pocket Without Coverage

Without insurance or if a claim is denied, branded Eliquis carries a retail price of approximately $598 to $620 per 30-day supply (5 mg twice daily) at major U.S. pharmacies as of mid-2025. Generic apixaban is substantially less, approximately $18 to $45 per 30-day supply at pharmacies using GoodRx or similar discount programs, though these discounts cannot be combined with insurance benefits. [4]

The Bristol-Myers Squibb/Pfizer Eliquis360 copay assistance program offers eligible commercially insured patients a copay as low as $10 per month. This program is not available to patients covered by Medicare, Medicaid, TRICARE, or any other federal or state healthcare program. For those patients, the manufacturer's patient assistance program (PAP) provides free branded drug to patients meeting income thresholds (generally below 400% of the federal poverty level).

The ARISTOTLE trial data reinforce why abandoning anticoagulation for cost reasons carries measurable risk. Among patients with atrial fibrillation who discontinued oral anticoagulants, the annualized stroke rate increases by roughly 3.7 strokes per 100 patient-years compared to those remaining on therapy. [2] That number should frame any cost-benefit conversation between clinician and patient.

How to Appeal a Prior Authorization Denial for Eliquis

A PA denial from Priority Health is not a final answer. Federal and Michigan state law guarantee multiple levels of appeal. The process, in sequence, is: internal appeal (submitted within 60 days of denial), external independent review (requested after internal appeal exhaustion), and, if applicable, an expedited appeal for urgent clinical situations (decision required within 72 hours under Michigan Department of Insurance and Financial Services rules).

Successful appeal submissions typically include the following elements:

1. The prescriber's clinical letter explaining the specific indication, dose, and why Eliquis is the appropriate drug for this patient given their comorbidities, renal function, and bleeding-risk profile.
2. Relevant lab results (serum creatinine, CBC, INR history if prior warfarin use documented).
3. Citations to current clinical guidelines. The 2023 ACC/AHA/ACCP/HRS guideline states that apixaban produces "superior efficacy and safety" compared with warfarin in patients with atrial fibrillation and normal or mildly impaired renal function. [6]
4. Any adverse event or contraindication documentation for step-therapy drugs (warfarin, rivaroxaban, dabigatran).
5. Patient-specific factors such as polypharmacy with CYP3A4 or P-glycoprotein inducers/inhibitors that affect the pharmacokinetics of alternative DOACs differently than apixaban.

Industry data from the Kaiser Family Foundation's 2023 analysis found that insurers deny approximately 17% of in-network claims. Of those denials that reach the appeal stage, 39% to 54% are reversed, depending on plan type and whether the appeal is internal or external. [9] A well-documented appeal from a board-certified cardiologist or hematologist carries substantially higher reversal odds than a form submission without supporting clinical documentation.

Comparing Eliquis Coverage to Other DOACs on Priority Health Formularies

Priority Health formularies generally include all four FDA-approved DOACs: apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). Rivaroxaban and dabigatran are often placed at the same tier as branded Eliquis, though once-daily dosing of rivaroxaban sometimes makes it a preferred step-therapy drug on plans seeking to enforce adherence protocols.

The clinical decision between DOACs is not purely formulary-driven. The ENGAGE AF-TIMI 48 trial (N=21,105) showed that edoxaban 60 mg once daily was non-inferior to warfarin for stroke prevention but was associated with significantly more hemorrhagic strokes in the warfarin arm, a nuance that affects patient selection. [10] RE-LY (N=18,113) demonstrated that dabigatran 150 mg twice daily reduced stroke by 35% versus warfarin but increased GI bleeding rates by approximately 1.5-fold. [11] These trial-specific safety and efficacy differences mean prescribers have legitimate clinical grounds to specify a particular DOAC, and documenting that rationale strengthens a PA submission or appeal considerably.

For renal-impaired patients, apixaban's predominantly hepatic elimination (approximately 73% nonrenal clearance) makes it the preferred DOAC across the major nephrology and cardiology societies for patients with CrCl 15-29 mL/min, a point that can anchor a medical necessity argument when step therapy requires rivaroxaban or dabigatran first. [12]

Medicare Advantage and Eliquis: Special Considerations for Priority Health Seniors

Priority Health's Medicare Advantage plans operate under Part D formulary rules set by CMS. Starting January 1, 2025, the Inflation Reduction Act caps out-of-pocket drug spending at $2,000 per year for all Part D enrollees, a change that dramatically affects the affordability of Eliquis for seniors who previously reached the coverage gap. [5]

CMS requires that Medicare Part D formularies include at least two anticoagulants. Priority Health's Medicare formularies typically include both branded Eliquis and generic apixaban, as well as at least one other DOAC. On these plans, prior authorization criteria must meet CMS guidelines prohibiting overly restrictive access to medically necessary drugs.

Seniors who feel their Priority Health Medicare Advantage formulary placement or PA denial is unfair can request a coverage determination, then an appeal through Priority Health, then escalate to an Independent Review Entity (IRE) contracted by CMS. The IRE must issue a standard decision within 7 calendar days or an expedited decision within 72 hours for urgent cases.

A 2022 OIG report found that Medicare Advantage plans denied 13% of prior authorization requests that were for services meeting Medicare coverage criteria. [13] For anticoagulants specifically, the report noted that step-therapy requirements were among the most common sources of inappropriate denial.

Practical Steps for Patients Right Now

If you are a Priority Health member who needs Eliquis and faces a coverage question, the most direct path forward involves three parallel actions. Call Priority Health member services to confirm the current formulary status and PA requirements for your specific plan ID. Ask your prescriber's office to submit a PA request the same day rather than waiting for a pharmacy rejection notice to trigger the process. Request a 30-day bridge supply of samples or an emergency supply from your pharmacist while the PA processes, as Michigan law requires urgent-access protections for chronic medications.

If cost is a barrier even after coverage is confirmed, ask your cardiologist or primary care physician whether generic apixaban is appropriate for your situation. For most patients with nonvalvular atrial fibrillation or VTE, the 2024 American Heart Association science advisory confirms that switching from branded Eliquis to FDA-approved generic apixaban is clinically acceptable. [14]

Patients at Priority Health whose annual out-of-pocket costs for Eliquis will exceed $2 to 000 in a Medicare plan year should contact the Extra Help (Low Income Subsidy) program through Social Security, which can reduce Part D cost-sharing to as little as $4.50 per fill for generic drugs in 2025. [5]